The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 3 of the 7 sources its claims cite were checked for support.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Open accessAbstract
BACKGROUND: Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or death in this population. METHODS: We randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alone (control group). Treatment was to continue until the occurrence of disease progression or unacceptable side effects. The primary end point was progression-free survival. RESULTS: white cells) (P<0.001). The most common adverse events of grade 3 or 4 were neutropenia (50.0% in the daratumumab group vs. 35.3% in the control group), anemia (11.8% vs. 19.7%), lymphopenia (15.1% vs. 10.7%), and pneumonia (13.7% vs. 7.9%). CONCLUSIONS: Among patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than among those who received lenalidomide and dexamethasone alone. A higher incidence of neutropenia and pneumonia was observed in the daratumumab group. (Funded by Janssen Research and Development; MAIA ClinicalTrials.gov number, NCT02252172.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
24 Own result · 5 Own method · 4 Own interpretation · 2 Partly supported · 1 Supported so far · 1 No full text of the sources · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The phase 3 Southwest Oncology Group (SWOG) S0777 trial of lenalidomide plus dexamethasone with or without bortezomib in patients with newly diagnosed myeloma for whom immediate autologous stem-cell transplantation was not indicated showed that the triplet combination resulted in longer progression-free survival (median, 41 months vs. 29 months; hazard ratio, 0.74), including among patients who”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
- Also stated in: § CONCLUSIONS · boosted
“these findings established the regimen of lenalidomide and dexamethasone as standard of care.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Abstract > BACKGROUND
What the sources say
- Not checked — no full text of the sourcecites [5] source
- Supportedcites [17] source
The Introduction calls lenalidomide plus dexamethasone one of the standards of care for newly diagnosed multiple myeloma and specifically lists it as a treatment option for patients ineligible for autologous stem-cell transplant. This directly supports the citing sentence. (LLM, conf=0.94)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § CONCLUSIONS · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, in the CASTOR and POLLUX trials, among patients with relapsed or refractory multiple myeloma who had a high-risk cytogenetic profile, substantial benefits with respect to progression-free survival and minimal residual disease with daratumumab plus standard-of-care regimens were observed after a longer follow-up period.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Efficacy section (p. 9) says the longer-follow-up POLLUX progression-free survival benefit was maintained across cytogenetic-risk subgroups, and the Discussion (p. 11) reports higher MRD-negativity rates overall. It does not establish an MRD benefit specifically in high-risk patients. Its CASTOR comparison (Discussion, p. 11) concerns patients with one prior therapy, not the high-risk cytogenetic subgroup. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [25] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Prespecified subgroup analyses of progression-free survival confirmed the superiority of the daratumumab regimen over the control regimen across all subgroups, except in the subgroup of patients who had hepatic impairment at baseline (Fig. 2).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The progression-free survival benefit was maintained among patients 75 years of age or older (hazard ratio, 0.63; 95% CI, 0.44 to 0.92).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the patients who had a response (partial response or better), 80.3% (95% CI, 75.1 to 84.5) in the daratumumab group and 65.7% (95% CI, 58.6 to 71.8) in the control group sustained the response for 30 months.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Daratumumab plus lenalidomide and dexamethasone was associated with a higher incidence of neutropenia and infections.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Negative status for minimal residual disease was associated with longer progression-free survival than positive status, regardless of the trial treatment (Fig. S3 in the Supplementary Appendix).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of patients with an overall response was 92.9% in the daratumumab group and 81.3% in the control group (P<0.001).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of infections of any grade was 86.3% in the daratumumab group and 73.4% in the control group; the incidence of grade 3 or 4 infections was 32.1% in the daratumumab group and 23.3% in the control group.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > SAFETY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 7
- Probably not a substantial claim. 3
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our trial population was notably older; 99% of the patients were 65 years of age or older, and 44% were 75 years of age or older.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median progression-free survival was not reached in the daratumumab group and was 31.9 months (95% CI, 28.9 to not reached) in the control group.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this trial involving patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, the addition of daratumumab to lenalidomide and dexamethasone resulted in significantly longer progression-free survival, a higher response rate, an increased depth of response, and a longer duration of response than lenalidomide and dexamethasone alone.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Randomization was stratified according to International Staging System disease stage (I vs. II vs. III, with higher stages indicating more severe disease) (see Table S1 in the Supplementary Appendix for details on the staging criteria), geographic region (North America vs. other), and age (<75 vs. ≥75 years).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Methods > RANDOMIZATION AND TREATMENT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We estimated that a sample of 730 patients would provide the trial with 80% power to detect a risk of disease progression or death that was 25% lower with daratumumab plus lenalidomide and dexamethasone than with lenalidomide and dexamethasone alone, using a log-rank test at a two-sided alpha level of 0.05.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Methods > STATISTICAL ANALYSIS
hedgeddirectn = 730- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary analysis was performed in the intention-to-treat population, which included all patients who underwent randomization.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Methods > STATISTICAL ANALYSIS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of patients who discontinued treatment because of these adverse events was low in our trial and was consistent with the safety profile observed in the POLLUX and ALCYONE trials, the latter of which represents a similar population of patients with newly diagnosed myeloma who were ineligible for stem-cell transplantation.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alone (control group).”
- Also stated in: § PATIENTS AND TREATMENT · plain
“A total of 737 patients were randomly assigned — 368 to the daratumumab group and 369 to the control group.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Abstract > METHODS
plainn = 737- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § PATIENTS AND TREATMENT · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although patients in the daratumumab group received treatment for a longer period of time, they received less lenalidomide than the control group, possibly owing to a higher incidence of adverse events that led to dose discontinuations or dose modifications in this group.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“However, the incidence of grade 3 or 4 infections was 29% with lenalidomide and dexamethasone in the primary analysis of the FIRST trial,5 which was consistent with the incidence in our trial (32.1% in the daratumumab group and 23.3% in the control group).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
What the sources say
- Not checked — no full text of the sourcecites [5] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DRd is approved for patients with newly diagnosed myeloma based on the results of an international multicenter randomized trial which showed benefit over lenalidomide plus dexamethasone (Rd).97”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [97]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Daratumumab, an anti-CD38–targeting monoclonal antibody (mAb), is a cornerstone of standard-of-care MM regimens with demonstrated survival benefit across all lines.9–14”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Meta-analyses suggest that indefinite maintenance therapy is superior in terms of survival outcomes36”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [36]
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationInternational Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522 · cited 2×
“‖ Cytogenetic risk was based on fluorescence in situ hybridization or karyotype analysis; patients who had a high-risk cytogenetic profile had at least one high-risk abnormality (del17p, t[14;16], or t[4;14]).”
BackgroundMethodSelf-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citation
Cited by
Sorted by citations
Diagnosis and Management of Multiple Myeloma
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L., Tuazon, S. A., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,082
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
“DRd has been recently approved for patients with newly diagnosed myeloma, based on the results of an international multicenter randomized trial.(87) PFS at 30 months was higher with DRd compared with Rd, 70.”
BackgroundMethodvan de Donk, N. W. C. J., Pawlyn, C., & Yong, K. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 935
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 830
“Daratumumab, lenalidomide, dexamethasone (DRd) has shown significant activity in patients who are not candidates for transplantation, and is an additional alternative to VRd.(88)”
BackgroundMethodInfluentialVoorhees, P. M., Kaufman, J. L., Laubach, J. P., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R. W., Costa, L. J., Anderson, L. D., et al. (2020) · Blood · doi:10.1182/blood.2020005288 · Cited by 717
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Mateos, M., Cavo, M., Bladé, J., Dimopoulos, M. A., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32956-3 · Cited by 447
Self-citationD’Agostino, M., Cairns, D. A., Lahuerta, J. J., Wester, R., Bertsch, U., Waage, A., Zamagni, E., Mateos, M., Dall’Olio, D., van de Donk, N. W. C. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02614 · Cited by 452
“917 (0) 750 (23) 585 (36) 437 (42) 326 (47) 252 (52) 188 (76) 133 (102) 83 (137) 47 (162) 24 (181) 195 (0) 141 (5) 93 (6) 63 (8) 45 (10) 32 (11) 26 (14) 20 (19) 10 (27) 7 (27) 3 (31) Time (months)”
Self-citationCavo, M., Gay, F., Beksaç, M., Pantani, L., Petrucci, M. T., Dimopoulos, M. A., Dozza, L., van der Holt, B., Zweegman, S., Oliva, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30099-5 · Cited by 386
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00466-6 · Cited by 370
Self-citationMultiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 373
Self-citationMalard, F., Neri, P. E., Bahlis, N. J., Terpos, E., Moukalled, N. M., Hungria, V., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 387
Self-citationClinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
Oliva, S., D’Agostino, M., Boccadoro, M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00001 · Cited by 291
“(50) NTE NDMM: - DaraRd arm (368) - Rd arm (369) NGS (10−5 ) Longitudinal Dara-Rd: 24.”
BackgroundIsatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Facon, T., Dimopoulos, M.-A., Leleu, X. P., Beksac, M., Pour, L., Hájek, R., Liu, Z., Minarik, J., Moreau, P., Romejko-Jarosinska, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400712 · Cited by 284
Self-citationMultiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljević, M., Campagnaro, E. L., Castillo, J. J., Chandler, J. C., Costello, C. L., Efebera, Y. A., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 283
Self-citationMoreau, P., Kumar, S. K., Miguel, J. F. S., Davies, F. E., Zamagni, E., Bahlis, N. J., Ludwig, H., Mikhael, J. R., Terpos, E., Schjesvold, F. H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30756-7 · Cited by 290
“The approval of daratumumab-based regimens (dara-tumumab plus bortezomib plus melphalan plus prednisone [ALCYONE trial] 41,42 and daratumumab plus lenalidomide plus dexamethasone [MAIA trial] 43 ) as the front-line therapy for myeloma is making treat-ment decisions challenging.”
Self-citationCosta, L. J., Chhabra, S., Medvedova, E., Dholaria, B., Schmidt, T. M., Godby, K. N., Silbermann, R. W., Dhakal, B., Bal, S., Giri, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01935 · Cited by 269
“(%) Bone disease 43 (81) 29 (63) 18 (75) 90 (73) Renal failure 2 (4) 8 (17) 6 (25) 16 (13) Anemia 22 (42) 30 (65) 20 (83) 72 (59) Hypercalcemia 8 (15) 7 (15) 7 (29) 22 (18) Immunoglobulin isotype, No.”
InfluentialKumar, S. K., Jacobus, S. J., Cohen, A. D., Weiss, M., Callander, N., Singh, A. K., Parker, T. L., Menter, A., Yang, X., Parsons, B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30452-6 · Cited by 245
Self-citationMateos, M., Nahi, H., Legiec, W. M., Grosicki, S., Vorobyev, V. I., Špıčka, I., Hungria, V., Korenkova, S., Bahlis, N. J., Flogegård, M., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30070-3 · Cited by 259
Self-citationDurie, B. G. M., Hoering, A., Sexton, R., Abidi, M. H., Epstein, J., Rajkumar, S. V., Dispenzieri, A. A., Kahanic, S. P., Thakuri, M. C., Reu, F. J., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0311-8 · Cited by 258
Self-citationBahlis, N. J., Dimopoulos, M. A., White, D. J., Benboubker, L., Cook, G., Leiba, M., Ho, P. J., Kım, K., Takezako, N., Moreau, P., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0711-6 · Cited by 237
“Consistent tolerability was also observed with daratumumab in the phase 3 MAIA study of D-Rd versus Rd in patients with NDMM who are ineligible for transplantation (median follow-up, 28 months) [15].”
BackgroundSelf-citationMultiple Myeloma: Available Therapies and Causes of Drug Resistance
Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 241
“More recently, several randomized trials showed a significant benefit for NDMM patients when adding daratumumab to the standard regimens with bortezomib, melphalan and prednisone [88], bortezomib, thalidomide and dexamethasone [89] or lenalidomide and dexamethasone [90].”
BackgroundATP and cancer immunosurveillance
Kepp, O., Bezu, L., Yamazaki, T., Virgilio, F. D., Smyth, M. J., Kroemer, G., & Galluzzi, L. (2021) · The EMBO Journal · doi:10.15252/embj.2021108130 · Cited by 238
“However, CD38-specific agents (including the FDA-approved monoclonal antibody daratumumab) are currently used with the aim of eradicating CD38-expressing myeloma cells (Facon et al , 2019), and ENPP1 blockers are still in preclinical development (Carozza et al , 2020).”
Palladini, G. O., Kastritis, E., Maurer, M. S., Zonder, J. A., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Bumma, N., Kaufman, J. L., et al. (2020) · Blood · doi:10.1182/blood.2019004460 · Cited by 212
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Martin, T. G., Corzo, K., Chiron, M., van de Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., Wiederschain, D., et al. (2019) · Cells · doi:10.3390/cells8121522 · Cited by 166
“gov, NCT02195479 demonstrated favorable results with the addition of daratumumab to standard induction therapies in subgroup analyses of untreated MM patients with high-risk disease, although interpretation of these results is limited due to the small number of patients [89,90].”
ResultCAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
Zhang, X., Zhang, H., Lan, H., Wu, J., & Xiao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1101495 · Cited by 181
“With the increasing understanding of MM pathogenesis and the application of novel therapeutic agents, such as proteasome inhibitors (bortezomib, ixazomib, and carfi lzomib), immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide), and monoclonal antibodies (daratumumab, isatuximab, and elotuzumab), as wel…”
BackgroundDimopoulos, M., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hájek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 188
“DaraRd 72 , DaraVM plus prednisone 73 and VRd 74 are the SOC regimens previously recommended by the EHA 11,12 for the treatment of transplant-ineligible patients with NDMM.”
Self-citationNCCN Guidelines Insights: Multiple Myeloma, Version 1.2020
Kumar, S. K., Callander, N. S., Hillengaß, J., Liedtke, M., Baljević, M., Campagnaro, E. L., Castillo, J. J., Chandler, J. C., Cornell, R. F., Costello, C. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0049 · Cited by 161
Self-citationGoldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R. R., Nievergall, E., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00263-0 · Cited by 167
Self-citationMateos, M., Sonneveld, P., Hungria, V., Nooka, A. K., Estell, J. A., Barreto, W. G., Corradini, P., Min, C., Medvedova, E., Weisel, K. C., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.623 · Cited by 166
Self-citationChromosome 1q21 abnormalities in multiple myeloma
Schmidt, T. M., Fonseca, R., & Usmani, S. Z. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00474-8 · Cited by 154
Self-citationEmerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 160
San-Miguel, J., Avet-Loiseau, H., Paiva, B., Kumar, S., Dimopoulos, M. A., Facon, T., Mateos, M.-V., Touzeau, C., Jakubowiak, A., Usmani, S. Z., et al. (2022) · Blood · doi:10.1182/blood.2020010439 · Cited by 153
Self-citationLeypoldt, L. B., Tichy, D., Besemer, B., Hänel, M., Raab, M. S., Mann, C., Munder, M., Reinhardt, H. C., Nogai, A., Görner, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01696 · Cited by 158
“It is allowed to include patients in the trial after 1 cycle (4 weeks) of any antimyeloma fi rst-line treatment 4.”
BackgroundSelf-citationPérez, C., Botta, C., Zabaleta, A., Puig, N., Cedena, M., Goicoechea, I., Alameda, D., José‐Eneriz, E. S., Merino, J., Rodríguez‐Otero, P., et al. (2020) · Blood · doi:10.1182/blood.2019004537 · Cited by 153
Usmani, S. Z., Facon, T. T. F., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M. J., Pour, L., Martí, J. M., Basu, S., Cohen, Y. C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03485-7 · Cited by 152
“…observed with frontline daratumumab plus lenalidomide and dexamethasone (D-Rd) triplet therapy versus lenalidomide and dexamethasone (Rd) alone in the phase 3 MAIA study 8,13,14 , which set a new benchmark for the transplant-ineligible population, with a median overall survival of 7.5 years 14 .”
InfluentialSelf-citationDimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Suzuki, K., Plesner, T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00940 · Cited by 140
“0 (1-63) cycles; the median (range) duration of daratumumab monotherapy was 5.”
BackgroundSelf-citationMultiple myeloma: the (r)evolution of current therapy and a glance into future
Gullà, A., & Anderson, K. C. (2020) · Haematologica · doi:10.3324/haematol.2020.247015 · Cited by 143
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Sonneveld, P., Chanan-Khan, A. A., Weisel, K. C., Nooka, A. K., Masszi, T., Beksaç, M., Špıčka, I., Hungria, V., Munder, M., Mateos, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02734 · Cited by 129
“0 (1-63), and median (range) duration of daratumumab monotherapy was 9.”
BackgroundSelf-citationFacon, T. T. F., Cook, G., Usmani, S. Z., Hulin, C., Kumar, S. K., Plesner, T., Touzeau, C., Bahlis, N. J., Basu, S., Nahi, H., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01488-8 · Cited by 129
“The safety profile of D-Rd in frailty subgroups was generally consistent with the overall population of MAIA [14]; although higher rates of grade 3/4 neutropenia and pneumonia were observed with D-Rd in the frail subgroup than in the total–non-frail subgroup, these events were clinically manageable.”
BackgroundMethodResultInfluentialSelf-citationUsmani, S. Z., Hoering, A., Ailawadhi, S., Sexton, R., Lipe, B. C., Hita, S., Valent, J. N., Rosenzweig, M. A., Zonder, J. A., Dhodapkar, M. V., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30354-9 · Cited by 131
Self-citationCosta, L. J., Derman, B. A., Bal, S., Sidana, S., Chhabra, S., Silbermann, R. W., Ye, J. C., Cook, G., Cornell, R. F., Holstein, S. A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01012-4 · Cited by 148
“testing all patients to testing only those with CR [15, 17, 19, 22, 28, 54, 73].”
BackgroundSelf-citationMultiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
Dimopoulos, M. A., Moreau, P., Terpos, E., et al. (2021) · PubMed · doi:10.1097/hs9.0000000000000528 · Cited by 124
“001).(45) Other approved regimens in this setting include bendamustine plus prednisone(46) and melphalan, prednisone and lenalidomide (MPR),(47) but they are not routinely used and cannot be considered as standards of care.”
BackgroundSelf-citationMultiple myeloma with high-risk cytogenetics and its treatment approach
Hanamura, I. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03353-5 · Cited by 126
“The phase 3 MAIA study showed that the addition of Dara to Rd significantly improved PFS and MRD-negativity rates [110] (Table 2).”
BackgroundPathway network of pyroptosis and its potential inhibitors in acute kidney injury
Li, N., Wang, Y., Wang, X., Sun, N., & Gong, Y.-H. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106033 · Cited by 129
Leleu, X. P., Hulin, C., Lambert, J., Bobin, A., Perrot, A., Karlin, L., Roussel, M., Montes, L., Chérel, B., Chalopin, T., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03050-2 · Cited by 121
“…approved in combination with lenalidomide and dexamethasone (the triplet-based DRd regimen) in patients with newly diagnosed multiple myeloma (NDMM) that are transplant-ineligible (TI) and is considered the best SOC to date on the basis of a median progression-free survival (PFS) of 62 months 1–3 .”
Self-citationDaratumumab or active monitoring for high-risk smoldering multiple myeloma
Dimopoulos, M. A., Voorhees, P. M., Schjesvold, F., Cohen, Y. C., Hungria, V., Sandhu, I., Lindsay, J., Baker, R. I., Suzuki, K., Kosugi, H., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409029 · Cited by 121
Self-citationTeclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2514663 · Cited by 119
Self-citationLandgren, O., Hultcrantz, M. L., Diamond, B. T., Lesokhin, A. M., Mailankody, S., Hassoun, H., Tan, C. R. C., Shah, U. A., Lu, S. X., Salcedo, M., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0611 · Cited by 120
Dimopoulos, M. A., Jakubowiak, A. J., McCarthy, P. L., Orlowski, R. Z., Attal, M., Bladé, J., Goldschmidt, H., Weisel, K. C., Ramasamy, K., Zweegman, S., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0273-x · Cited by 116
Self-citationImmune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 113
Usmani, S. Z., Nahi, H., Plesner, T., Weiss, B. M., Bahlis, N. J., Belch, A., Voorhees, P. M., Laubach, J. P., van de Donk, N. W. C. J., Ahmadi, T., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30081-8 · Cited by 109
Self-citationGiri, S., Grimshaw, A. A., Bal, S., Godby, K. N., Kharel, P., Djulbegović, B., Dimopoulos, M. A., Facon, T. T. F., Usmani, S. Z., Mateos, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4338 · Cited by 107
Self-citationCavo, M., Miguel, J. F. S., Usmani, S. Z., Weisel, K. C., Dimopoulos, M. A., Avet‐Loiseau, H., Paiva, B., Bahlis, N. J., Plesner, T., Hungria, V., et al. (2021) · Blood · doi:10.1182/blood.2021011101 · Cited by 108
Self-citationFacon, T., Venner, C. P., Bahlis, N. J., Offner, F., White, D. J., Karlin, L., Benboubker, L., Rigaudeau, S., Rodon, P., Voog, E., et al. (2021) · Blood · doi:10.1182/blood.2020008787 · Cited by 104
Self-citationBahlis, N. J., Baz, R., Harrison, S. J., Quach, H., Ho, S.-J., Vangsted, A. J., Plesner, T., Moreau, P., Gibbs, S. D., Coppola, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00443 · Cited by 91
Self-citationOgiya, D., Liu, J., Ohguchi, H., Kurata, K., Samur, M. K., Tai, Y.-T., Adamia, S., Ando, K., Hideshima, T., & Anderson, K. C. (2020) · Blood · doi:10.1182/blood.2019004332 · Cited by 92
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
Viola, D., Donà, A., Caserta, E., Troadec, E., Besi, F., McDonald, T., Ghoda, L. Y., Gunes, E. G., Sanchez, J. F., Khalife, J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0810-4 · Cited by 90
Anti CD38 monoclonal antibodies for multiple myeloma treatment
Gozzetti, A., Ciofini, S., Simoncelli, M., Santoni, A., Pacelli, P., Raspadori, D., & Bocchia, M. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2052658 · Cited by 89
Emerging agents and regimens for multiple myeloma
Yang, Y., Li, Y., Gu, H., Dong, M., & Cai, Z. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00980-5 · Cited by 87
Zand, L., Rajkumar, S. V., Leung, N., Sethi, S. M., Ters, M. E., & Fervenza, F. C. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020101541 · Cited by 86
Daratumumab for treatment‐refractory antibody‐mediated diseases in neurology
Scheibe, F., Ostendorf, L., Prüß, H., Radbruch, H., Aschman, T., Hoffmann, S., Blau, I., Meisel, C., Alexander, T., & Meisel, A. (2022) · European Journal of Neurology · doi:10.1111/ene.15266 · Cited by 88
“Comorbidity of Patient #6 with smoldering multiple myeloma required treatment according to the MAIA protocol [12] for the first eight cycles followed by 12 further daratumumab cycles at monthly intervals.”
MethodCAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Rodríguez‐Lobato, L. G., Ganzetti, M., de Larrea, C. F., Hudecek, M., Einsele, H., & Danhof, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01243 · Cited by 88
“SLAMF7 is highly expressed on malignant plasma cells both, in NDMM and RRMM, regardless of the cytogenetic risk stratification (85).”
BackgroundInfluentialLarocca, A., Bonello, F., Gaïdano, G., D’Agostino, M., Offidani, M., Cascavilla, N., Capra, A., Benevolo, G., Tosi, P., Galli, M., et al. (2021) · Blood · doi:10.1182/blood.2020009507 · Cited by 85
“There is no evidence that lenalidomide improves the outcome of patients with high-risk cytogenetics; 2,23 triplets or more intensive regimens including newer drugs 5,6,24 are needed to overcome their bad prognosis.”
Dimopoulos, M. A., Špıčka, I., Quach, H., Oriol, A., Hájek, R., Garg, M. K., Beksaç, M., Bringhen, S., Katodritou, E., Chng, W. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02060 · Cited by 81
“These patients may receive continuous treatment with one or more agents received as induction, such as lenalidomide(9,14,15) and/or daratumumab.(8,16) In routine clinical practice, treatment duration may be limited because of toxicity and route of administration.”
BackgroundSelf-citationNovel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
Puertas, B., González‐Calle, V., Sobejano, E., Escalante, F., Queizán, J. A., Bárez, A., Labrador, J., Alonso, J. M., de Coca, A. G., Cantalapiedra, A. M. T., et al. (2023) · Cancers · doi:10.3390/cancers15051558 · Cited by 88
“Currently, the standard of care (SoC) for MM consists of a combination of PIs and/or IMiDs and/or anti-CD38 antibodies [11,12], followed by ASCT and maintenance when the patient is eligible [13–17].”
BackgroundResultDuan, M., Nguyen, D. C., Joyner, C. J., Saney, C. L., Tipton, C. M., Andrews, J., Lonial, S., Kim, C. M., Hentenaar, I., Kosters, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112682 · Cited by 85
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Jasielec, J. K., Kubicki, T., Raje, N. S., Vij, R., Reece, D. E., Berdeja, J. G., Derman, B. A., Rosenbaum, C. A., Richardson, P. G. G., Gurbuxani, S. K., et al. (2020) · Blood · doi:10.1182/blood.2020007522 · Cited by 74
Self-citationCho, S., Lin, L., Xing, L., Li, Y., Wen, K., Yu, T., Hsieh, P. A., Munshi, N. C., Wahl, J., Matthes, K., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002524 · Cited by 78
“Lenalidomide (len) and pomalidomide (pom), 2 immunomodulatory drugs (IMiDs), are routinely used as a therapeutic backbone or partners in various MM treatment combinations throughout all disease settings.(31-35) IMiDs have direct antiproliferative and proapoptotic effects on MM, in addition to indirect anti-MM activity…”
BackgroundCurrent approaches to management of newly diagnosed multiple myeloma
Goel, U., Usmani, S. Z., & Kumar, S. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26512 · Cited by 76
“No significant difference in PFS was found between KCd + ASCT + KCd and KRd alone (53 months vs. 55.3 months, HR = 0.88, p = .45).24 Nevertheless, KCd may be a more economical alternative for NDMM as compared to VRd.77 4.1.2 | Quadruplet regimens Daratumumab is a monoclonal antibody targeting CD38.”
BackgroundInfluentialSelf-citationPoczta, A., Rogalska, A., & Marczak, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091841 · Cited by 78
“The addition of daratumumab improved the efficacy of both VMP and RD [82].”
BackgroundHow I treat multiple myeloma in geriatric patients
Facon, T. T. F., Leleu, X. P., & Manier, S. (2023) · Blood · doi:10.1182/blood.2022017635 · Cited by 72
Self-citationVirus-specific T-cell therapies for patients with primary immune deficiency
Keller, M. D., & Bollard, C. M. (2020) · Blood · doi:10.1182/blood.2019000924 · Cited by 67
Multiple myeloma with acute light chain cast nephropathy
Leung, N., & Rajkumar, S. V. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00806-w · Cited by 67
Stege, C. A. M., Nasserinejad, K., van der Spek, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03143 · Cited by 66
“t(14;16) 2 out of 55 (4) High-risk cytogenetic disease 11 out of 56 (20)”
BackgroundInfluentialRosiñol, L., Oriol, A., Ríos, R., Blanchard, M. J., Jarque, I., Bargay, J., Hernández, M. T., Cabañas, V., Carrillo‐Cruz, E., Sureda, A. M., et al. (2023) · Blood · doi:10.1182/blood.2022019531 · Cited by 66
Offidani, M., Corvatta, L., Morè, S., Nappi, D., Martinelli, G., Olivieri, A., & Cerchione, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.624661 · Cited by 64
“As regard patients ineligible for ASCT, a great efficacy of daratumumab-containing combinations was reported by the phase III trials ALCYONE and MAIA, exploring daratumumab–bortezomib–melphalan–prednisone (DVMP) vs VMP and daratumumab–lenalidomide–dexamethasone (DRd) vs Rd, respectively.”
BackgroundInfluentialHou, J., Ye, J. C., Pu, J. J., Liu, H., Ding, W., Zheng, H., & Liu, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01077-3 · Cited by 64
Kumar, S., Baizer, L., Callander, N. S., Giralt, S. A., Hillengass, J., Freidlin, B., Hoering, A., Richardson, P. G., Schwartz, E. I., Reiman, A., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00695-5 · Cited by 62
“TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY DISEASE With current therapies, patients with MM will experience their first relapse at variable intervals after diagnosis [7, 11, 12].”
BackgroundMethodSelf-citationFacon, T. T. F., Moreau, P., Weisel, K. C., Goldschmidt, H., Usmani, S. Z., Chari, A., Plesner, T., Orlowski, R. Z., Bahlis, N. J., Basu, S., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02505-2 · Cited by 63
Self-citationMohan, M., Weinhold, N., Schinke, C., Thanedrarajan, S., Rasche, L., Sawyer, J. R., Tian, E., van Rhee, F., & Zangari, M. (2019) · British Journal of Haematology · doi:10.1111/bjh.16292 · Cited by 61
“More recently daratumumab combinations have shown clinical benefit in transplant-ineligible newly diagnosed multiple myeloma (NDMM) and is currently FDA-approved in the up-front setting in combination with melphalan/bortezomib and lenalidomide/dexamethasone (Mateos et al., 2018; Facon et al., 2019).”
BackgroundTreatment and disease‐related complications in multiple myeloma: Implications for survivorship
Chakraborty, R., & Majhail, N. S. (2020) · American Journal of Hematology · doi:10.1002/ajh.25764 · Cited by 65
Engelhardt, M. M., Ihorst, G., Duque‐Afonso, J., Wedding, U., Spät-Schwalbe, E., Goede, V., Kolb, G. F., Stauder, R., & Wäsch, R. (2020) · Haematologica · doi:10.3324/haematol.2019.242958 · Cited by 58
Mateos, M., Dimopoulos, M. A., Cavo, M., Suzuki, K., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., Pour, L., Grosicki, S., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.06.005 · Cited by 57
Self-citationMelflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
Mateos, M., Bladé, J., Bringhen, S., Ocio, E. M., Efebera, Y. A., Pour, L., Gay, F., Sonneveld, P., Gullbo, J., & Richardson, P. G. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103120 · Cited by 60
Multiple Myeloma in the Time of COVID-19
Saleh, A. S. A., Sher, T., & Gertz, M. A. (2020) · Acta Haematologica · doi:10.1159/000507690 · Cited by 57
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Franssen, L. E., Stege, C. A. M., Zweegman, S., van de Donk, N. W. C. J., & Nijhof, I. S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041195 · Cited by 58
Sive, J. I., Cuthill, K., Hunter, H. M., Kazmi, M. A., Pratt, G., Smith, D., & British Society of Haematology (2021) · British Journal of Haematology · doi:10.1111/bjh.17410 · Cited by 62
“Daratumumab has been added to various induction regi- mens, demonstrating improved RR and PFS for NTE patients in combination with RD,84 and both PFS and OS with VMP,85,86 and PFS for TE patients in combination with VTD.84,87 OS data remain immature, but PFS data provide early evidence of benefit, and it is likely to…”
MethodHow to Treat High-Risk Myeloma at Diagnosis and Relapse
Caro, J., Hadidi, S. A., Usmani, S. Z., Yee, A. J., Raje, N. S., & Davies, F. E. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320105 · Cited by 58
Self-citationDeveloping next generation immunomodulatory drugs and their combinations in multiple myeloma
Thakurta, A., Pierceall, W. E., Amatangelo, M. D., Flynt, E., & Agarwal, A. (2021) · Oncotarget · doi:10.18632/oncotarget.27973 · Cited by 59
“Similarly, the demonstration that LENdex improved progression-free survival (PFS) compared to previously established standard therapies such as melphalan, thalidomide, and prednisone (MPT) in NDMM transplant ineligible patients paved the way to investigate combination studies with bortezomib and DARA (SWOG S0777, MAIA…”
BackgroundMonoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action
Wudhikarn, K., Wills, B., & Lesokhin, A. M. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101143 · Cited by 56
“9%) was observed in the daratumumab group (13).”
BackgroundOrgueira, A. M., González, M. S., Arias, J. Á. D., Rodríguez, B. A., Vence, N. A., López, Á. B., Blanco, A. A., Pérez, L. B., Raíndo, A. P., López, M. C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01286-2 · Cited by 57
“These predictions need to be evaluated in other cohorts and in the context of the current realistic combinations that incorporate monoclonal antibodies and other immunotherapic approaches [44, 45].”
BackgroundAdditivity predicts the efficacy of most approved combination therapies for advanced cancer
Hwangbo, H., Patterson, S. C., Dai, A., Plana, D., & Palmer, A. C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00667-z · Cited by 56
Perspectives on the Treatment of Multiple Myeloma
Rafae, A., van Rhee, F., & Hadidi, S. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad306 · Cited by 65
Current Treatment Strategies for Multiple Myeloma
Branagan, A. R., Lei, M. M., Lou, U. Y., & Raje, N. S. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00244 · Cited by 56
Self-citationEvaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
Dima, D., Dower, J., Comenzo, R. L., & Varga, C. (2020) · Cancer Management and Research · doi:10.2147/cmar.s212526 · Cited by 56
Balmaceda, N. B., Aziz, M., Chandrasekar, V. T., McClune, B. L., Kambhampati, S., Shune, L. O., Abdallah, A.-O. A., Anwer, F., Majeed, A., Qazilbash, M. H., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08451-x · Cited by 57
“Facon (2019) [20] MAIA 3 ND Daratumumab/lenalidomide/dexamethasone 364 73 25.”
BackgroundMaura, F., Boyle, E. M., Coffey, D. G., Maclachlan, K. H., Gagler, D. C., Diamond, B. T., Ghamlouch, H., Blaney, P., Ziccheddu, B., Cirrincione, A. M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00657-1 · Cited by 59
“0 peaks) and point mutations/indels in 80 MM driver genes 16,26,27 (Supplementary Tables 7–9).”
InfluentialSelf-citation
Metadata
- Authors
- Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Attal, M., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Ahmadi, T., Chiu, C., Wang, J., Van Rampelbergh, R., Uhlar, C. M., Kobos, R., Qi, M., & Usmani, S. Z.
- Affiliations
- Université de Lille (FR)
- Mayo Clinic (US)
- University of Southern Denmark (DK)
- The University of Texas MD Anderson Cancer Center (US)
- University of Calgary (CA)
- Karolinska University Hospital (SE)
- The University of Melbourne (AU)
- From University of Lille, Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, Lille (T.F.), Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.), Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac (C.H.), Hematology Department, University Hospital, Vandoeuvre lès Nancy (A.P.), Service d’Hématologie, CHU de Toulouse–Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse (M.A.), Department of Hematology, Vendée Hospital, La...
- University of Alberta (CA)
- Hôpital Necker-Enfants Malades (FR)
- Inserm (FR)
- ORCID
- Facon, Thierry
- Kumar, Shaji
- Plesner, Torben
- Orlowski, Robert Z.
- Moreau, Philippe
- Bahlis, Nizar
- Basu, Supratik
- Nahi, Hareth
- Hulin, Cyrille
- Quach, Hang
- Goldschmidt, Hartmut
- Perrot, Aurore
- Venner, Christopher P.
- Weisel, Katja
- Raje, Noopur
- Attal, Michel
- Macro, Margaret
- Frenzel, Laurent
- Leleu, Xavier
- Ahmadi, Tahamtan
- Chiu, Christopher
- Wang, Jianping
- Qi, Ming
- Usmani, Saad Z.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-05-30
- Volume
- 380
- Issue
- 22
- Pages
- 2104-2115
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10045721
- OpenAlex
- W2947874495
- Cited by
- 1,045
- References
- 32
- Citations by year
- 2026: 105 · 2025: 111 · 2024: 107 · 2023: 130 · 2022: 145 · 2021: 208 · 2020: 195 · 2019: 39
- FWCI
- 107.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, other-oa)
- Wolverhampton Intellectual Repository and E-Theses (University of Wolverhampton) (acceptedVersion, cc-by-nc-nd)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Funders
- Janssen Research and Development (-)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- daratumumab, lenalidomide, dexamethasone, newly diagnosed multiple myeloma, progression-free survival, minimal residual disease, complete response, neutropenia, adverse events, autologous stem cell transplantation ineligibility, monoclonal antibody therapy, combination therapy, anemia, lymphopenia
- MeSH terms
- Lenalidomide, Progression-Free Survival, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neutropenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
